NasdaqGM - Nasdaq Real Time Price USD

Aurinia Pharmaceuticals Inc. (AUPH)

4.9100 +0.0400 (+0.82%)
At close: April 26 at 4:00 PM EDT
4.9001 -0.01 (-0.20%)
After hours: April 26 at 7:43 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Peter S. Greenleaf M.B.A. President, CEO & Director 1.34M -- 1970
Mr. Joseph M. Miller CPA Chief Financial Officer 791.92k -- 1974
Mr. Matthew Maxwell Donley M.B.A. Executive Vice President of Operations & Strategy 811.82k -- 1969
Mr. Stephen P. Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer 739.68k -- 1982
Dr. Volker Knappertz D.Sc., M.D. Executive Vice President of Research & Development 742.85k -- 1965
Andrea Levin Christopher Head of the Corporate Communications & Investor Relations -- -- --
Mr. Fran Lynch Vice President of Sales -- -- --
Mr. Michael R. Martin Chief Business Officer 350.57k -- 1972
Ms. Sue Evans Senior Vice President of Global Regulatory Affairs -- -- --
Mr. Scott Habig Chief Commercial Officer -- -- 1960

Aurinia Pharmaceuticals Inc.

118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487 https://www.auriniapharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
300

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Corporate Governance

Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 2; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Aurinia Pharmaceuticals Inc. Earnings Call

Related Tickers

TGTX TG Therapeutics, Inc.
13.47
-3.16%
 
BCRX BioCryst Pharmaceuticals, Inc.
4.1600
0.00%
 
HEPA Hepion Pharmaceuticals, Inc.
1.3700
+6.20%
 
AXSM Axsome Therapeutics, Inc.
71.71
+0.27%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
 
ARDX Ardelyx, Inc.
6.42
+1.74%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
AMLX Amylyx Pharmaceuticals, Inc.
1.7600
-1.12%
 
OCUL Ocular Therapeutix, Inc.
4.7450
+12.98%